ACVT Medical Imaging tech achieves 98% in FDA trials

From the LBT annual report:

A ten-week pivotal clinical trial at TriCore Reference Laboratories in New Mexico during July and August 2015 tested APAS against a panel of microbiologists. Culture plates from 5,500 patients were processed by APAS and simultaneously assessed by a panel of independent qualified microbiologists. The results showed that APAS achieved over 98% sensitivity in its detection of disease-causing bacteria in the samples.

This is a great result for the ACVT-developed technology.

This entry was posted in Medical Imaging, News, Research, Technology Transfer and tagged , , , . Bookmark the permalink.

Comments are closed.